published meta-analysis   sensitivity analysis   studies

ivermectin in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsI-TECH (Lim), 2022 0.31 [0.09; 1.09] Krolewiecki, 2020 0.49 [0.01; 26.05] Shahbaznejad, 2020 2.21 [0.07; 67.87] 0.40[0.13; 1.23]I-TECH (Lim), 2022, Krolewiecki, 2020, Shahbaznejad, 202030%608moderatenot evaluable deathsdetailed resultsGonzalez (IVER), 2020 0.83 [0.23; 3.02] Hashim A, 2020 0.48 [0.11; 1.99] I-TECH (Lim), 2022 0.31 [0.09; 1.09] Kirti, 2021 0.12 [0.01; 2.36] Krolewiecki, 2020 0.49 [0.01; 26.05] NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25] 0.43[0.21; 0.87]Gonzalez (IVER), 2020, Hashim A, 2020, I-TECH (Lim), 2022, Kirti, 2021, Krolewiecki, 2020, NCT04523831 (Mahmud), 202060%1,223moderatenot evaluable clinical deteriorationdetailed resultsHashim A, 2020 0.40 [0.10; 1.63] I-TECH (Lim), 2022 1.25 [0.87; 1.80] NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84] 0.68[0.29; 1.59]Hashim A, 2020, I-TECH (Lim), 2022, NCT04523831 (Mahmud), 2020378%993moderatenot evaluable clinical improvementdetailed resultsNCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38] 1.89[1.06; 3.38]NCT04523831 (Mahmud), 202010%400NAnot evaluable clinical improvement (7-day)detailed resultsKirti, 2021 0.90 [0.77; 1.06] NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93] 1.28[0.61; 2.70]Kirti, 2021, NCT04523831 (Mahmud), 2020291%475moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsNCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38] 1.89[1.06; 3.38]NCT04523831 (Mahmud), 202010%400NAnot evaluable death or ventilationdetailed resultsGonzalez (IVER), 2020 0.89 [0.30; 2.64] 0.89[0.30; 2.64]Gonzalez (IVER), 202010%73NAnot evaluable hospital dischargedetailed resultsGonzalez (IVER), 2020 0.71 [0.15; 3.40] Kirti, 2021 1.20 [0.73; 1.98] 1.14[0.71; 1.84]Gonzalez (IVER), 2020, Kirti, 202120%185moderatenot evaluable mechanical ventilationdetailed resultsI-TECH (Lim), 2022 0.41 [0.13; 1.30] Kirti, 2021 0.20 [0.00; 8.69] Shahbaznejad, 2020 2.24 [0.19; 25.88] 0.52[0.19; 1.42]I-TECH (Lim), 2022, Kirti, 2021, Shahbaznejad, 202030%675moderatenot evaluable viral clearance detailed resultsChaccour, 2020 0.92 [0.77; 1.09] 0.92[0.77; 1.09]Chaccour, 202010%24NAnot evaluable viral clearance by day 7detailed resultsChaccour, 2020 0.92 [0.77; 1.09] Kirti, 2021 0.80 [0.43; 1.50] 0.91[0.77; 1.08]Chaccour, 2020, Kirti, 202120%136lownot evaluable ICU admissiondetailed resultsI-TECH (Lim), 2022 0.78 [0.27; 2.23] Kirti, 2021 0.90 [0.30; 2.70] 0.84[0.39; 1.78]I-TECH (Lim), 2022, Kirti, 202120%602moderatenot evaluable serious adverse eventsdetailed resultsKrolewiecki, 2020 1.00 [0.03; 31.59] NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58] 2.14[0.21; 21.56]Krolewiecki, 2020, NCT04523831 (Mahmud), 202020%408moderatenot evaluable adverse eventsdetailed resultsChaccour, 2020 1.00 [0.20; 5.07] Krolewiecki, 2020 1.53 [0.42; 5.58] NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77] 1.97[0.55; 7.04]Chaccour, 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020336%432moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-03-29 15:23 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 684,886 - roots T: 290